Biomaterial Database

Lysozyme enhancement of tumor cell immunoprotection in a murine fibrosarcoma. 1981

J S Warren, and J J Rinehart, and B S Zwilling, and J A Neidhart

We examined the ability of human lysozyme (HLZM) to enhance the immunogenicity of a methylcholanthrene-induced murine fibrosarcoma of C57BL/10 mice. Following s.c. injection of 10(4) live tumor cells, 100% of mice developed palpable tumors within 16 +/- 3 (S.D.) days. Prechallenge immunization with 10(6) irradiated tumor cells with or without complete Freund's adjuvant resulted in protection from tumor development in 14 and 22% of mice, respectively. Incubation of tumor cells with HLZM prior to immunization approximately doubled the degree of protection, with 42 to 44% of mice remaining free of tumor. This enhanced protection was dependent on the enzymatic activity of HLZM. These data suggest that HLZM enhances tumor cell immunogenicity in this model.

UI	MeSH Term	Description	Entries
D007114	Immunization	Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).	Immunologic Stimulation,Immunostimulation,Sensitization, Immunologic,Variolation,Immunologic Sensitization,Immunological Stimulation,Sensitization, Immunological,Stimulation, Immunologic,Immunizations,Immunological Sensitization,Immunological Sensitizations,Immunological Stimulations,Sensitizations, Immunological,Stimulation, Immunological,Stimulations, Immunological,Variolations
D009113	Muramidase	A basic enzyme that is present in saliva, tears, egg white, and many animal fluids. It functions as an antibacterial agent. The enzyme catalyzes the hydrolysis of 1,4-beta-linkages between N-acetylmuramic acid and N-acetyl-D-glucosamine residues in peptidoglycan and between N-acetyl-D-glucosamine residues in chitodextrin. EC 3.2.1.17.	Lysozyme,Leftose,N-Acetylmuramide Glycanhydrolase,Glycanhydrolase, N-Acetylmuramide,N Acetylmuramide Glycanhydrolase
D009368	Neoplasm Transplantation	Experimental transplantation of neoplasms in laboratory animals for research purposes.	Transplantation, Neoplasm,Neoplasm Transplantations,Transplantations, Neoplasm
D004306	Dose-Response Relationship, Immunologic	A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell.	Immunologic Dose-Response Relationship,Relationship, Immunologic Dose-Response,Dose Response Relationship, Immunologic,Dose-Response Relationships, Immunologic,Immunologic Dose Response Relationship,Immunologic Dose-Response Relationships,Relationship, Immunologic Dose Response,Relationships, Immunologic Dose-Response
D005260	Female		Females
D006084	Graft Rejection	An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient.	Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D000276	Adjuvants, Immunologic	Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.	Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000818	Animals	Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA.	Animal,Metazoa,Animalia
D012513	Sarcoma, Experimental	Experimentally induced neoplasms of CONNECTIVE TISSUE in animals to provide a model for studying human SARCOMA.	EHS Tumor,Sarcoma, Engelbreth-Holm-Swarm,Sarcoma, Jensen,Experimental Sarcoma,Experimental Sarcomas,Sarcomas, Experimental,Engelbreth-Holm-Swarm Sarcoma,Jensen Sarcoma,Sarcoma, Engelbreth Holm Swarm,Tumor, EHS
D051379	Mice	The common name for the genus Mus.	Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

J S Warren, and J J Rinehart, and B S Zwilling, and J A Neidhart

Oxygen enhancement ratio of a murine fibrosarcoma.

January 1992, International journal of radiation oncology, biology, physics,

J S Warren, and J J Rinehart, and B S Zwilling, and J A Neidhart

Thermal enhancement of the effect of ifosfamide against a spontaneous murine fibrosarcoma, FSa-II.

January 1997, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group,

J S Warren, and J J Rinehart, and B S Zwilling, and J A Neidhart

Enhancement of pulmonary metastasis of murine fibrosarcoma NR-FS by ozone exposure.

January 1987, Journal of toxicology and environmental health,

J S Warren, and J J Rinehart, and B S Zwilling, and J A Neidhart

Photodynamic therapy: tumor volume limitation and tumor response for murine fibrosarcoma.

January 1990, Lasers in surgery and medicine,

J S Warren, and J J Rinehart, and B S Zwilling, and J A Neidhart

Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma.

February 1992, Journal of the National Cancer Institute,

J S Warren, and J J Rinehart, and B S Zwilling, and J A Neidhart

Tumor-specific active enhancement of a murine sarcoma.

January 1971, Tissue antigens,